Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. DOCS
DOCS logo

DOCS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Doximity Inc (DOCS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
24.390
1 Day change
-1.30%
52 Week Range
76.510
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Doximity Inc (DOCS) does not present a strong buy opportunity for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock's technical indicators, options data, and financial performance suggest a neutral position, while analyst ratings and recent trends indicate mixed-to-negative sentiment. Given the lack of strong positive catalysts and the absence of Intellectia Proprietary Trading Signals, holding off on a purchase is recommended.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 68.407, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 24.399), suggesting limited upside potential in the short term.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The options data indicates a slightly bullish sentiment with a low put-call ratio, but the implied volatility is high (90.5), suggesting significant uncertainty.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
4

Positive Catalysts

  • The company's revenue increased by 9.76% YoY in Q3 2026, and analysts have highlighted the potential for long-term growth driven by its AI tool suite and sticky platform with network effects.

Neutral/Negative Catalysts

  • Net income dropped by 18.14% YoY, and EPS fell by 16.22% YoY, reflecting declining profitability. Analysts have lowered price targets and expressed concerns about slower market growth, competitive risks, and limited visibility into spending shifts. The absence of recent news or significant trading trends further weakens the case for immediate investment.

Financial Performance

In Q3 2026, Doximity's revenue grew by 9.76% YoY to $185.05M. However, net income declined by 18.14% YoY to $61.56M, and EPS dropped by 16.22% YoY to $0.31. Gross margin also decreased slightly to 89.89%. The financial performance indicates revenue growth but declining profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed. Recent downgrades and lowered price targets reflect concerns about slower growth, competitive risks, and limited near-term catalysts. However, some analysts maintain a Buy rating, citing potential long-term growth opportunities and undervaluation.

Wall Street analysts forecast DOCS stock price to rise
18 Analyst Rating
Wall Street analysts forecast DOCS stock price to rise
14 Buy
4 Hold
0 Sell
Strong Buy
Current: 24.710
sliders
Low
25
Averages
42.75
High
63
Current: 24.710
sliders
Low
25
Averages
42.75
High
63
Truist
Buy
to
Hold
downgrade
$37 -> $29
AI Analysis
2026-04-20
New
Reason
Truist
Price Target
$37 -> $29
AI Analysis
2026-04-20
New
downgrade
Buy
to
Hold
Reason
Truist downgraded Doximity to Hold from Buy with a price target of $29, down from $37. The firm has a taken a more cautious outlook on Doximity, saying its revenue growth visibility has softened and structural risks are mounting. There is limited clarity on pharma digital marketing budgets, the analyst tells investors in a research note. Truist believes Doximity's fiscal 2027 growth profile will likely be below consensus while it faces emerging competitive pressure from AI-native platforms such as OpenEvidence.
Truist
Buy
to
Hold
downgrade
$29
2026-04-19
New
Reason
Truist
Price Target
$29
2026-04-19
New
downgrade
Buy
to
Hold
Reason
Truist downgraded Doximity to Hold from Buy with a $29 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for DOCS
Unlock Now

People Also Watch